Official Title: “An Open-label, Phase 2 Trial of Orally Administered PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma (GBM)”
This open-label Phase 2 trial will study the efficacy of PF 00299804 in adult patients with recurrent WHO grade IV malignant glioma (glioblastoma) with epidermal growth factor receptor (EGFR) gene amplification. This research will help determine whether treatment with PF-00299804 is a rational approach to treating patients with GBM. In addition, this research will help determine whether tailoring a targeted therapy to a specific genetic subpopulation of tumors is a feasable and effective approach in the GBM population.
Study Type: Interventional
Study Design: Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Study Primary Completion Date: April 2012
Zitat von und den englischen Volltext gibt es hier: http://clinicaltrials.gov/show/NCT01036477
